High rate of serious infection in juvenile idiopathic arthritis patients under biologic therapy in a real-life setting

Nenhuma Miniatura disponível
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
Citação
MODERN RHEUMATOLOGY, v.28, n.2, p.264-270, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objectives: To assess the rate of serious and/or opportunistic infections in juvenile idiopathic arthritis (JIA) patients from a single tertiary center under biologic therapy and to identify possible risk factors associated to these complications.Methods: A total of 107 JIA patients followed at the biologic therapy center of our tertiary university hospital using a standardized electronic database protocol including demographic data, clinical and laboratorial findings and treatment at baseline and at the moment of infection. Opportunistic infections included tuberculosis, herpes zoster and systemic mycosis.Results: A total of 398 patient-yrs(py) were included. The median time of biologic exposure was 3.0 years (0.15-11.5). We observed 35 serious/opportunistic infectious events in 27 (25%) patients: 31(88.6%) were serious infections and four (11.4%) opportunistic infections. Serious/opportunistic infections rates were 10.6/100py for ETN, 10.9/100py for ADA, 2.6/100py for ABA and 14.8/100py for TCZ. Comparison of 27 patients with and 80 without infection showed a higher frequency of systemic-onset JIA, lower age at biologic therapy initiation and a history of previous serious infection (p<.05) in the former group.Conclusions: This study demonstrated a high rate of serious infections in JIA patients under biologic therapy in a real-life setting. Systemic-onset JIA, lower age at biologic therapy start and history of previous serious infections were important risk factors for these complications. Also, higher rates of severe infections comparing to the former studies was possibly due to elevated MTX doses in our patients.
Palavras-chave
Juvenile idiopathic arthritis, serious infection, opportunistic infection, biologic
URI
https://observatorio.fm.usp.br/handle/OPI/26252
Referências
  1. Aikawa NE, 2013, SCAND J RHEUMATOL, V42, P34, DOI 10.3109/03009742.2012.709272
  2. Aikawa NE, 2016, REV BRAS REUMATOL, V56, P478, DOI 10.1016/j.rbre.2015.08.004
  3. Aikawa NE, 2015, VACCINE, V33, P604, DOI 10.1016/j.vaccine.2014.12.030
  4. Becker I, 2017, ARTHRIT CARE RES, V69, P552, DOI 10.1002/acr.22961
  5. Beukelman T, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1109-8
  6. Beukelman T, 2013, ARTHRITIS RHEUM-US, V65, P1384, DOI 10.1002/art.37866
  7. Beukelman T, 2012, ARTHRITIS RHEUM-US, V64, P2773, DOI 10.1002/art.34458
  8. Beukelman T, 2011, ARTHRIT CARE RES, V63, P465, DOI 10.1002/acr.20460
  9. Brunelli Juliana Barbosa, 2016, Rev Bras Reumatol, DOI 10.1016/j.rbr.2016.09.005
  10. Brunner HI, 2015, ANN RHEUM DIS, V74, P1110, DOI 10.1136/annrheumdis-2014-205351
  11. Cantini F, 2014, J RHEUMATOL, V41, P56, DOI 10.3899/jrheum.140103
  12. Consolaro A, 2009, ARTHRIT RHEUM-ARTHR, V61, P658, DOI 10.1002/art.24516
  13. Davies R, 2015, ARTHRITIS RHEUMATOL, V67, P2487, DOI 10.1002/art.39197
  14. De Benedetti F, 2012, NEW ENGL J MED, V367, P2385, DOI 10.1056/NEJMoa1112802
  15. FERRAZ MB, 1990, J RHEUMATOL, V17, P813
  16. Horneff G, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1170-3
  17. Horneff G, 2015, CURR RHEUMATOL REP, V17, DOI 10.1007/s11926-015-0542-z
  18. Hurd A, 2013, CURR RHEUMATOL REP, V15, DOI 10.1007/s11926-013-0327-1
  19. Lovell DJ, 2008, ARTHRITIS RHEUM, V58, P1496, DOI 10.1002/art.23427
  20. Lovell DJ, 2006, ARTHRITIS RHEUM, V54, P1987, DOI 10.1002/art.21885
  21. Machado CSM, 2001, CLIN EXP RHEUMATOL, V19, pS25
  22. Nimmrich S, 2015, RHEUMATOL INT, V35, P465, DOI 10.1007/s00296-014-3197-6
  23. Petty RE, 2004, J RHEUMATOL, V31, P390
  24. Ringold S, 2013, ARTHRITIS RHEUM-US, V65, P2499, DOI 10.1002/art.38092
  25. Sterba Y, 2016, CURR RHEUMATOL REP, V18, DOI 10.1007/s11926-016-0593-9
  26. Tarkiainen M, 2015, RHEUMATOLOGY, V54, P1170, DOI 10.1093/rheumatology/keu457
  27. Toussi SS, 2013, CLIN INFECT DIS, V57, P1318, DOI 10.1093/cid/cit489
  28. Tsiodras S, 2008, MAYO CLIN PROC, V83, P181
  29. van Riel PLCM, 2014, CLIN EXP RHEUMATOL, V32, pS65
  30. Walters HM, 2015, CLIN RHEUMATOL, V34, P457, DOI 10.1007/s10067-014-2779-8
  31. Whitmer T, 2015, J VIROL, V89, P8687, DOI 10.1128/JVI.01149-15
  32. Yasui K, 2014, PEDIATR RHEUMATOL, V12, DOI 10.1186/1546-0096-12-45
  33. Yokota S, 2016, ANN RHEUM DIS, V75, P1654, DOI 10.1136/annrheumdis-2015-207818

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - FM/MPE
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/ICr
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - LIM/36
Carregar mais